| Literature DB >> 18513449 |
Ylva C Strandberg Lutzow1, Laurelea Donaldson, Christian P Gray, Tony Vuocolo, Roger D Pearson, Antonio Reverter, Keren A Byrne, Paul A Sheehy, Ross Windon, Ross L Tellam.
Abstract
BACKGROUND: Mastitis in dairy cattle results from infection of mammary tissue by a range of micro-organisms but principally coliform bacteria and Gram positive bacteria such as Staphylococcus aureus. The former species are often acquired by environmental contamination while S. aureus is particularly problematic due to its resistance to antibiotic treatments and ability to reside within mammary tissue in a chronic, subclinical state. The transcriptional responses within bovine mammary epithelial tissue subjected to intramammary challenge with S. aureus are poorly characterised, particularly at the earliest stages of infection. Moreover, the effect of infection on the presence of bioactive innate immune proteins in milk is also unclear. The nature of these responses may determine the susceptibility of the tissue and its ability to resolve the infection.Entities:
Mesh:
Year: 2008 PMID: 18513449 PMCID: PMC2430192 DOI: 10.1186/1746-6148-4-18
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Dose of S. aureus (bacteria/5 ml) given by intramammary infusion into each udder quarter
| 1490 | PBS | 5 × 102 | 1 × 104 | 1 × 105 |
| 1592 | 1 × 104 | PBS | 1 × 105 | 1 × 106 |
| 1419 | PBS | nil1 | 1 × 105 | 1 × 106 |
1 This quarter was not used
Pathology of milk samples 16 h post-infusion
| Dose1 | 5 × 102 | 1 × 104 | 1 × 105 | ||
| Growth2 | Minor8 | + | + | + | |
| Gramstain3 | - | + | + | + | |
| Hemolysis4 | - | partial | partial | + | |
| Catalase5 | - | + | + | + | |
| Coagulase6 | - | + | + | + | |
| Isolate7 | n.d. | ||||
| Dose | 1 × 104 | 1 × 105 | 1 × 106 | ||
| Growth | + | none | + | + | |
| Gramstain | + | - | + | + | |
| Hemolysis | partial | - | partial | partial | |
| Catalase | + | - | + | + | |
| Coagulase | + | - | + | + | |
| Isolate | none | ||||
| Dose | Nil | 1 × 105 | 1 × 106 | ||
| Growth | none | + | + | + | |
| Gramstain | - | + | + | + | |
| Hemolysis | - | partial | partial | partial | |
| Catalase | - | + | + | + | |
| Coagulase | - | + | + | + | |
| Isolate | none | ||||
1 Bacterial dose
2 Bacterial growth (+/-)
3 Gram positive or Gram negative
4 Hemolysis; hemolytic on blood agar (+, partial, -)
5 Catalase (+/-)
6Coagulase (+/-)
7Bacterial species identified
8 Minor bacterial growth was observed but this was not S. aureus.
Figure 1Relative expression of selected genes in mammary tissue challenged with . The relative gene expression levels of selected genes were measured by qRT-PCR. Samples were obtained from mammary tissues of three Holstein Friesian cows at peak lactation 16 hours following intramammary infusion with increasing doses of S. aureus into the separate udder quarters. Data for each gene are expressed as relative fold changes compared to expression in the intra-animal control tissue for each animal. The genes tested included: (a) α-S1-casein (CSN1S1) (turquoise diamond) and β-casein (CSN2) (red triangle); (b) Interleukin 8 (IL-8a) (blue square), Interleukin 1β (IL-1βb) (red diamond), Tumor necrosis factor α (TNFαc) (yellow diamond), Interleukin 6 (IL-6d) (green circle) and CD14 antigen (CD14e) (black triangle); (c) S100 calcium-binding protein A12 (S100A12f) (blue diamond) and Pentraxin-3 (PTX3g) (pink square). Expression data for each gene were analysed by ANOVA. The superscript letters are specific for each gene tested and signify significant differences (P < 0.01) between a specific infection dose and the corresponding intramammary control for each cow.
Figure 2Microarray experimental design. Gene expression in mammary tissue samples from each cow was analysed by microarray hybridisation using an 'all-pairs design'. The figure is a schematic representation of the microarray design used for each cow (except cow 1419 which only had 2 intramammary bacterial infusions), where each arrow represents one microarray slide with the direction of the arrow indicating the cDNA labelling from Cy5 to Cy3-labelled cDNA.
Figure 3Clusters of differentially expressed genes in response to intramammary infusion of . Microarrays were performed on tissue from each mammary quarter with data compared to the intramammary control for each cow to identify differentially expressed transcripts. The figure shows the mean gene expression cluster profiles for the significantly differentially expressed elements that were either up-regulated (a) or down-regulated (b) relative to the control in response to intramammary infusion of S. aureus. The clusters only contain significantly differentially expressed elements that were expressed in all samples and showed at least 2 fold change relative to the control in at least one sample. RNA samples were obtained from mammary tissue of three Holstein Friesian cows at peak lactation that had been infused with pyrogen-free PBS (dose 0, n = 3) in one quarter (intra-animal controls) and in other quarters with S. aureus at dose rates of 500 (n = 1), 10,000 (n = 2), 100,000 (n = 3) or 1,000,000 (n = 2) bacteria. Data are expressed as log2 (fold change) ± 1 S.D. for the centroid of the cluster.
Significantly up-regulated genes in mammary tissue challenged with S. aureus.
| Homo sapiens chemokine (C-C motif) ligand 11 (CCL11), mRNA | |||
| Bos taurus chemokine (C-C motif) ligand 2 (CCL2), mRNA. | |||
| Homo sapiens chemokine (C-C motif) ligand 20 (CCL20), mRNA | |||
| Homo sapiens chemokine (C-C motif) ligand 3-like 1 (CCL3L1), mRNA | |||
| Homo sapiens similar to cytokine (LOC388372), mRNA | |||
| Homo sapiens colony stimulating factor 3 (granulocyte) (CSF3), transcript variant 2, mRNA | |||
| Homo sapiens chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, | |||
| Homo sapiens chemokine (C-X-C motif) ligand 2 (CXCL2), mRNA | |||
| Homo sapiens chemokine (C-X-C motif) ligand 10 (CXCL10), mRNA | |||
| Bos taurus interleukin 1, beta (IL1B), mRNA. | |||
| Ovis aries interleukin 6 (IL6), mRNA | |||
| interferon-gamma; Bos taurus interferon, gamma or immune type [interferon gamma type 2] | |||
| Bos taurus interleukin 8 [neutrophil activating peptide 1] (IL8), mRNA. | |||
| Bos taurus leptin [obesity] (LEP), mRNA | |||
| Homo sapiens plasminogen activator, urokinase receptor (PLAUR), mRNA | |||
| Homo sapiens pentaxin-related gene, rapidly induced by IL-1 beta (PTX3), mRNA | |||
| Bos taurus S100 calcium binding protein A12 (calgranulin C) (S100A12), mRNA | |||
| Homo sapiens S100 calcium binding protein A2 (S100A2), mRNA | |||
| Homo sapiens thrombospondin 1 (THBS1), mRNA | |||
| Homo sapiens chemokine (C-C motif) receptor 1 (CCR1), mRNA | |||
| Homo sapiens CD14 antigen (CD14), mRNA | |||
| Homo sapiens tumor necrosis factor receptor superfamily, member 5 (TNFRSF5), transcript | |||
| Homo sapiens colony stimulating factor 3 receptor (granulocyte) (CSF3R), transcript variant | |||
| Homo sapiens interleukin 11 receptor, alpha (IL11RA), transcript variant 2, mRNA | |||
| Homo sapiens solute carrier family 2 (facilitated glucose transporter), member 4 (SLC2A4) | |||
| Homo sapiens toll-like receptor 2 (TLR2), mRNA | |||
| Homo sapiens toll-like receptor 4 (TLR4), transcript variant 4, mRNA | |||
| Homo sapiens tumor necrosis factor receptor superfamily, member 9 (TNFRSF9), mRNA | |||
| Homo sapiens cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A), transcript variant 2, mRNA | |||
| Homo sapiens FYVE, RhoGEF and PH domain containing 6 (FGD6), mRNA | |||
| Homo sapiens hypothetical protein FLJ20313 (FLJ20313), mRNA | |||
| Homo sapiens hemopoietic cell kinase (HCK), mRNA | |||
| Homo sapiens myristoylated alanine-rich protein kinase C substrate (MARCKS), mRNA | |||
| Homo sapiens MARCKS-like protein (MLP), mRNA | |||
| Homo sapiens MAD, mothers against decapentaplegic homolog (Drosophila) interacting | |||
| Homo sapiens HLA-B associated transcript 3 (BAT3), transcript variant 3, mRNA | |||
| Homo sapiens BCL2-related protein A1 (BCL2A1), mRNA | |||
| Homo sapiens baculoviral IAP repeat-containing 3 (BIRC3), transcript variant 2, mRNA | |||
| Homo sapiens immediate early response 3 (IER3), transcript variant short, mRNA | |||
| Homo sapiens activating transcription factor 3 (ATF3), mRNA | |||
| Homo sapiens BTG family, member 2 (BTG2), mRNA | |||
| Homo sapiens early growth response 1 (EGR1), mRNA | |||
| Homo sapiens v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS), mRNA | |||
| Homo sapiens jun B proto-oncogene (JUNB), mRNA | |||
| Homo sapiens nuclear factor of kappa light polypeptide gene enhancer in B-cells | |||
| Homo sapiens nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor | |||
| Homo sapiens nuclear receptor subfamily 2, group F, member 6 (NR2F6), mRNA | |||
| Homo sapiens acyl-CoA synthetase long-chain family member 6 (ACSL6), mRNA | |||
| Homo sapiens fucosyltransferase 8 (alpha (1,6) fucosyltransferase) (FUT8), transcript | |||
| Homo sapiens heat shock 70 kDa protein 1A (HSPA1A), mRNA | |||
| Homo sapiens hypothetical protein LOC286286 (LOC286286), mRNA | |||
| Homo sapiens nitric oxide synthase 2A (inducible, hepatocytes) (NOS2A), transcript variant | |||
| Homo sapiens superoxide dismutase 2, mitochondrial (SOD2), mRNA | |||
| Homo sapiens tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase) | |||
| Homo sapiens tubulin, alpha 1 (testis specific) (TUBA1), mRNA | |||
| Homo sapiens tryptophanyl-tRNA synthetase (WARS), mRNA |
Significantly down-regulated genes in mammary tissue challenged with S. aureus.
| Bovine interleukin 1-alpha (IL-1-alpha) mRNA, complete cds. | |||
| Homo sapiens nerve growth factor, beta polypeptide (NGFB), mRNA | |||
| Bos taurus interleukin-13 precursor (IL-13) mRNA, partial cds | |||
| Bos taurus resistin (RETN), mRNA | |||
| Homo sapiens secreted frizzled-related protein 1 (SFRP1), mRNA | |||
| Homo sapiens secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1) (SPP1), mRNA | |||
| Homo sapiens CD24 antigen (small cell lung carcinoma cluster 4 antigen) (CD24), | |||
| Homo sapiens erythrocyte membrane protein band 4.1-like 1 (EPB41L1), transcript | |||
| Homo sapiens filamin A, alpha (actin binding protein 280) (FLNA), mRNA | |||
| Homo sapiens integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor | |||
| Homo sapiens v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | |||
| Homo sapiens keratin 5 (epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber | |||
| Homo sapiens profilin 2 (PFN2), transcript variant 1, mRNA | |||
| Homo sapiens vascular cell adhesion molecule 1 (VCAM1), transcript variant 2, mRNA | |||
| Homo sapiens vinculin (VCL), transcript variant meta-VCL, mRNA | |||
| Homo sapiens vimentin (VIM), mRNA | |||
| Homo sapiens chemokine (C-X3-C motif) receptor 1 (CX3CR1), mRNA | |||
| Homo sapiens v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) | |||
| Homo sapiens fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2) | |||
| Homo sapiens v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) | |||
| Homo sapiens met proto-oncogene (hepatocyte growth factor receptor) (MET), mRNA | |||
| Homo sapiens platelet-derived growth factor receptor, alpha polypeptide (PDGFRA) | |||
| Homo sapiens transforming growth factor, beta receptor III (betaglycan, 300 kDa) | |||
| Homo sapiens pyrophosphatase (inorganic) (PP), mRNA | |||
| Homo sapiens protein phosphatase 1J (PP2C domain containing) (PPM1J), mRNA | |||
| Homo sapiens protein kinase C, alpha (PRKCA), mRNA | |||
| Homo sapiens ras homolog gene family, member B (RHOB), mRNA | |||
| Homo sapiens cell death-inducing DFFA-like effector a (CIDEA), transcript variant | |||
| Bos taurus clusterin (CLU), mRNA. | |||
| Homo sapiens EphA1 (EPHA1), mRNA | |||
| Homo sapiens EphA7 (EPHA7), mRNA | |||
| Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 (DDX5), mRNA | |||
| Homo sapiens nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent | |||
| Homo sapiens inactive progesterone receptor, 23 kD (TEBP), mRNA | |||
| Homo sapiens cathelicidin antimicrobial peptide (CAMP), mRNA | |||
| Homo sapiens casein alpha s1 (CSN1S1), mRNA | |||
| Homo sapiens hypothetical protein FLJ20920 (FLJ20920), mRNA | |||
| Homo sapiens glycine amidinotransferase (L-arginine:glycine amidinotransferase | |||
| Homo sapiens glutathione peroxidase 4 (phospholipid hydroperoxidase) (GPX4) | |||
| Bos taurus immunoglobulin IgA heavy chain constant region gene, partial cds | |||
| Cervus nippon 18S ribosomal RNA gene, partial sequence | |||
| Homo sapiens similar to Sorting nexin 19 (LOC399979), mRNA |
Figure 4Time-courses of . bMEC were stimulated with either 50 μg/ml LPS (■) or 20 μg/ml LTA (◇) and the expression levels of S100A12 (a) and PTX3 (b) were monitored using qRT-PCR over a 24 h period. Data are expressed as mean fold change (n = 3) compared to expression in unstimulated cells. Significance was determined by ANOVA compared to unstimulated bMEC. P < 0.01 (*) was considered significant.
Figure 5Purified S100A12 and PTX3 recombinant proteins. (a) SDS-PAGE analysis of rS100A12 purified using Ni-NTA affinity chromatography. All samples were run under reducing conditions. Lanes 1–4: 1, 2.5, 5 and 12.5 μg of rS100A12, respectively. (b) SDS-PAGE analysis of rPTX3 purified using Ni-NTA affinity chromatography. The samples were reduced and alkylated, and run under reducing conditions. Lanes 1–3: 1, 2 and 4 μg of rPTX3, respectively. (c) SDS-PAGE (lane 1) and immunoblot (lane 2) analyses of purified rtnPTX3 secreted by Trichoplusia ni cells. The samples were reduced and alkylated and run under reducing conditions. 10 μg of rtnPTX3 was used for the SDS-PAGE analysis and 5 μg for the immunoblot.
Figure 6Immunoblot analyses of S100A12 and PTX3 expression in milk whey from . Representative immunoblot analyses of milk whey proteins before and after infection of mammary tissue with S. aureus. Each sample comprised 25 μl of milk whey and was run under reducing conditions. (a) Representative analysis of S100A12 expression in milk whey from cow 1419. Lane 1, control quarter pre-infection; lane 2, control quarter post-infection; lane 3, pre-infection control from the quarter receiving 1 × 105 S. aureus; lane 4, post-infection sample (1 × 105 bacteria); lane 5, pre-infection control from the quarter receiving 1 × 106 S. aureus; lane 6, post-infection sample (1 × 106 bacteria). Arrows denote the positions of S100A12 immunoreactive oligomers (monomer, dimer, trimer) detected using the immunoaffinity purified antibodies raised to rS100A12. (b) Analysis of PTX3 expression in milk whey. Lane 1, cow 1419 pre-infection sample from the quarter receiving 1 × 105 S. aureus; lane 2, post-infection sample (1 × 105 bacteria); lane 3, cow 1419 pre-infection sample from the quarter receiving 1 × 106 S. aureus; lane 4, cow 1419 post-infection sample (1 × 106 bacteria); lane 5, cow 1490 pre-infection sample from the quarter receiving 1 × 105 S. aureus; lane 6, cow 1490 post-infection sample (1 × 105 bacteria); lane 7, cow 1592 pre-infection control from the quarter receiving 1 × 105 S. aureus; lane 8, cow 1592 post-infection sample (1 × 105 bacteria). Arrows denote the positions of PTX3 immunoreactive bands (monomer and dimer) detected using immunoaffinity purified antibodies raised to rPTX3.
Figure 7S100A12 and PTX3 expression in milk from . Antigen capture ELISAs were used to measure the concentrations of S100A12 (a) and PTX3 (b) in milk samples taken before and 16 h after the S. aureus intramammary challenge. Data from cows 1419, 1490 and 1592 were used in the analyses. Bars represent the means ± SEM for two independent samples. The asterisk denotes significant expression difference (1 way ANOVA, P < 0.01) compared with the corresponding post-infection control sample for each cow. No PTX3 expression could be detected in milk from the intra-animal control udders or in the pre-infection samples.
Figure 8Correlation between the Somatic Cell Count (SCC) and S100A12 concentration in milk from dairy cattle. The plot shows the correlation between S100A12 concentration and SCC in milk from 38 dairy cows. The line of best fit drawn through the data has a correlation coefficient (R2) of 0.92. The SCC was determined by flow cytometry of milk samples and the S100A12 levels in milk whey were determined using the S100A12-specific antigen capture ELISA with rS100A12 as the standard.
Figure 9Antimicrobial activity of rS100A12. Antimicrobial activities of rS100A12 were measured using the Broth Microdilution Susceptibility Testing Method. (a) E. coli and (b) S. aureus. (■), rS100A12; (▲) BSA at the same concentrations. Bars represent the means ± SEM for 2 replicates. The data were examined for significance using ANOVA and the asterisk denotes significant differences (P < 0.05) from the control.
Figure 10Binding of rtnPTX3 to immobilised human C1q. The binding of rtnPTX3 to immobilised human C1q was measured using an ELISA-based binding assay. The binding activities for two different preparations of rtnPTX3 (each 12.5 ng/well) are shown. The controls consisted of PBS and BSA (12.5 ng/well). Significance was measured by ANOVA relative to the PBS control (*, P < 0.05).
Figure 11Direct binding of biotinylated . The binding of biotinylated E. coli (ATCC 35218) to rtnPTX3 immobilised onto a nitro-cellulose membrane was measured. (a) PBS; (b) rPTX3 in duplicate (50 μg); and (c) BSA, in duplicate (50 μg).
Oligonucleotide primer sequences used for qRT-PCR and recombinant protein expression
| CAACCCTGAAGTGCTTGACAT | AGGCAGATGGATCAGCCA | 220 | [12] | ||
| AAATGAACCGAGAAGTGGTGTT | TTCCATATTCCTCTTGGGGTAGA | 185 | [12] | ||
| CTGGGTTCAATCAGGCGAT | CAGCAGGTCAGTGTTTGTGG | 206 | [12] | ||
| CTGTGTGAAGCTGCAGTTCT | TAAGCAGACCTCGTTTCCAT | 180 | [12] | ||
| CTGGTTCAGACACTCAGGTCCT | GAGGTAAAGCCCGTCAGCA | 183 | [12] | ||
| GGTGCTACCCGATGTGTCTG | AAGGGATTTCCGTCCAGAGT | 191 | [12] | ||
| CCTGTCTTGTGGCTGTTGCTCTTG | CATCTTCCTTTTGAATGTGCTTCTGCT | 282 | pc* | ||
| TCTGCCTCTGCTCCAGTCTT | AGGAGGGGGCATTCACTTT | 251 | pc* | ||
| CATTTCGACACCCTCAACAA | CTGTTTTCAGCACCCTGGAC | 184 | |||
| rS100A12 | CCGGATCCACTAAGCTGGAAGATCACCTGGAGG | CCAAGCTTTACTCTTTGTGGATATCTATGTGGGCTG | - | ||
| TATGCCATGGTGCTTTCAGA | CCAATGAACAATGGACAACAA | 182 | |||
| rPTX3 | ATGGATCCGAGAACTCAGATGATTATGAGCTCATGTA | AGAAGCTTTTAATAAACATACTGTGCTCCTCGTG | - | ||
| rtnPTX3 | GTGGATCCGGAGAACTCAGATGATTATGAGCTCATGTA | AGAAGCTTTTAATAAACATACTGTGCTCCTCGTG | - |
* Personal communication (Karen Matthews)